Avadel Cns patent expiration
1. Lumryz patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11602513 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
| US11602512 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
| US11766418 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
| US10973795 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
| US10736866 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
| US11896572 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
| US11000498 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
| US11986451 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
| US11504347 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
| US11052061 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
| US10272062 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
| US11400065 | AVADEL CNS | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
Jul, 2037
(12 years from now) | |
| US10952986 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
| US11826335 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
| US11839597 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
| US11065224 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
| US10925844 | AVADEL CNS | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
Feb, 2040
(15 years from now) | |
| US11583510 | AVADEL CNS | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
Feb, 2042
(17 years from now) | |
| US11779557 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Mar, 2042
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 01, 2026 |
| Orphan Drug Exclusivity(ODE-431) | May 01, 2030 |
Drugs and Companies using SODIUM OXYBATE ingredient
Market Authorisation Date: 01 May, 2023
Treatment: Treatment of narcolepsy-related cataplexy or excessive daytime sleepiness using a once-daily pharmaceutical formulation comprising an oxybate; Treatment of narcolepsy-related cataplexy or excessive da...
Dosage: FOR SUSPENSION, EXTENDED RELEASE
More Information on Dosage
LUMRYZ family patents
